A carregar...
Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy
BACKGROUND: Trastuzumab (Herceptin), an antagonist to the human epidermal growth factor 2 (HER2) receptor significantly decreases the rates of breast cancer recurrence and mortality by 50%. Despite therapeutic benefits, the risk of cardiotoxicity with trastuzumab ranges from 10–15% when administered...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2244612/ https://ncbi.nlm.nih.gov/pubmed/18272009 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1532-429X-10-5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|